Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | R/R DLBCL: impact of allo-HSCT conditioning on patient survival

Nilanjan Ghosh • 17 Jun 2020
EHA 2020
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Carmustine Cyclophosphamide Etoposide Fludarabine Melphalan Rituximab

Nilanjan Ghosh MD, PhD, of Levine Cancer Institute, Charlotte, NC, explores the impact of conditioning prior to allogeneic hematopoietic stem cell transplants (allo-HSCT) on survival for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Nilanjan Ghosh

5:45
Treatment effectiveness of venetoclax-based therapy after BTKi exposure in CLL/SLL
Nilanjan Ghosh • 14 Dec 2023
6:05
Real-world data on the effect of ibrutinib flexible dosing treatment strategies on TTNT in CLL/SLL
Nilanjan Ghosh • 14 Dec 2023
5:42
Comparative effectiveness of liso-cel vs conventional 2L chemotherapy in R/R LBCL
Nilanjan Ghosh • 8 Dec 2022
5:59
InformCLL registry analysis: ibrutinib vs chemoimmunotherapy for the first-line treatment of CLL/SLL
Nilanjan Ghosh • 8 Dec 2022

Related Videos

2:02
Phase II ANIMATE trial investigating PET response-adapted treatment using nivolumab in R/R cHL
Graham Collins • 29 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals